EP 1891106 A2 20080227 - NOVEL COMPOUNDS AS GLP-I AGONISTS
Title (en)
NOVEL COMPOUNDS AS GLP-I AGONISTS
Title (de)
NEUE VERBINDUNGEN ALS GLP-I-AGONISTEN
Title (fr)
NOUVEAUX COMPOSES UTILISES EN TANT QU'AGONISTES DE GLP-I
Publication
Application
Priority
- IN 2006000154 W 20060504
- IN 558MU2005 A 20050505
- IN 645MU2005 A 20050531
Abstract (en)
[origin: WO2007017892A2] The present invention describes a group of novel peptidomimetics useful for the treatment of diabetes. These compounds are defined by the general formula (I) as given below. A-X<SUB>1</SUB>- S<SUB>1</SUB>-Y-S<SUB>2</SUB>-X<SUB>2</SUB>-B (I)
IPC 8 full level
C07K 14/605 (2006.01)
CPC (source: EP KR)
A61P 3/04 (2017.12 - EP); A61P 3/06 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 9/12 (2017.12 - EP); A61P 13/12 (2017.12 - EP); A61P 17/02 (2017.12 - EP); A61P 27/12 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07K 14/605 (2013.01 - EP KR); A61K 38/00 (2013.01 - EP)
Citation (search report)
See references of WO 2007017892A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK YU
DOCDB simple family (publication)
WO 2007017892 A2 20070215; WO 2007017892 A3 20070920; AP 2007004227 A0 20071231; AU 2006277557 A1 20070215; BR PI0612471 A2 20160906; CA 2606894 A1 20070215; EA 200702419 A1 20080428; EP 1891106 A2 20080227; IL 187105 A0 20080209; JP 2008540402 A 20081120; KR 20080021636 A 20080307; MX 2007013655 A 20080124; NO 20075618 L 20080130
DOCDB simple family (application)
IN 2006000154 W 20060504; AP 2007004227 A 20060504; AU 2006277557 A 20060504; BR PI0612471 A 20060504; CA 2606894 A 20060504; EA 200702419 A 20060504; EP 06809915 A 20060504; IL 18710507 A 20071101; JP 2008509578 A 20060504; KR 20077028300 A 20071204; MX 2007013655 A 20060504; NO 20075618 A 20071106